Flagship explainer

How SUPERNUS PHARMACEUTICALS, INC. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$719M · 100%Cost of revenue$74.6M · 10%Gross profit$644M · 90%Operating income−$62.3M · −9%Income before tax−$49M · −7%Income tax−$10.5M · −1%Net income−$38.5M · −5%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$719M100%
Cost of revenue$74.6M10%
$644M90%
−$62.3M−9%
Income before tax−$49M−7%
Income tax−$10.5M−1%
−$38.5M−5%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set
Embed this chart

View the full SUPERNUS PHARMACEUTICALS, INC. analysis at Buy Like Buffett